Abstract
Ethyl acetate fraction of garlic (Allium sativum) inhibits the viability of MCF7 and HepG2 through induction of apoptosis and G2/M phase cell cycle arrest
Highlights
Despite advanced therapeutic strategies and approaches for cancer, it remains the most devastating disease that leads to death (de Mesquita et al, 2009)
EtOAc fraction inhibited cancer cells proliferation through induction of apoptosis and cell cycle arrest in G2/M phase. These in vitro results suggest that garlic EtOAc fraction or its main component could be used as an adjuvant to anticancer drug or can help in the development of new anticancer drugs based on components of this fraction
MTT assay was performed to evaluate the effect of garlic fractions by methylene chloride (MC), petroleum ether (PE), EtOAc, and B on the proliferation of human MCF7 and HepG2 cells
Summary
Despite advanced therapeutic strategies and approaches for cancer, it remains the most devastating disease that leads to death (de Mesquita et al, 2009). This study aimed to compare the anticancer effect of different garlic fractions on the MCF7 and HepG2 cells and determine the underlying mechanism. Garlic (Allium sativum) with its main component organosulfur compounds (OSCs) has an anticancer effect against a large verity of cancer cells. This anticancer effect was studied on individual garlic components, rather than fractions. Methods: we investigated the anticancer effect of different garlic fractions on the MCF7 and HepG2 cells and studied the underlying mechanism. EtOAc fraction inhibited cancer cells proliferation through induction of apoptosis (revealed by a significant increase in mRNA levels of apoptotic markers, Caspase 3 and Bax and a significant decrease in mRNA levels of the anti-apoptotic marker, Bcl2) and cell cycle arrest in G2/M phase (indicated by increase in number of MCF7 and HepG2 cells in this phase). Conclusions: These in vitro results suggest that garlic EtOAc fraction or its main component could be used as an adjuvant to anticancer drug or can help in the development of new anticancer drugs based on components of this fraction
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
